Grail's Galleri Test Wins FDA Nod—Medicare Fight Looms

An FDA advisory panel has endorsed Grail's Galleri multi-cancer early detection test, a regulatory milestone the company has pursued since it began submitting data to the agency. The endorsement moves Galleri closer to formal clearance and gives Grail a credible claim to scientific validation. But the vote that matters most to the company's revenue line hasn't been scheduled, and it won't be cast by the FDA. It will be cast by the Centers for Medicare & Medicaid Services.

FDA Panel Backs Grail's Galleri Test: What the Approval Means

Advisory panel endorsements are not approvals, but they are the clearest signal the FDA can send before a final decision. Panels are convened when a product raises novel scientific or clinical questions, and their votes typically carry substantial weight with agency reviewers. For Galleri, the panel's backing validates the core premise of multi-cancer early detection: that a blood draw can flag signals of cancer across multiple organ sites before symptoms prompt conventional screening.

That premise has been commercially promising and analytically difficult in equal measure. Grail's test is designed to detect cancer signals in cell-free DNA shed into the bloodstream, a category known as liquid biopsy. Unlike a single-cancer screening test, which measures against a defined disease and a defined screening population, an MCED test must perform across dozens of cancer types, many of which have no recommended screening pathway at all. That breadth is the product's selling point and the source of the evidentiary burden regulators and payers apply to it.

For investors, the panel vote removes one category of risk. Regulatory rejection would have been terminal for the near-term commercial thesis. Instead, Grail now holds something closer to a conditional green light — conditional because FDA backing does not bind any payer, and because the clinical utility question, whether detecting these cancers earlier actually extends or improves lives, is the question payers will press hardest.

The Medicare Coverage Battle: Why It Matters More Than FDA Approval

Medicare is not a nice-to-have for a test like Galleri. It is the addressable market. Adults 65 and older carry the highest cancer incidence of any demographic group in the United States, which means the population Medicare covers overlaps almost perfectly with the population an MCED screening test is built to serve. Commercial insurers, by contrast, tend to follow Medicare's coverage decisions rather than lead them, particularly for novel diagnostics without established clinical guidelines.

CMS coverage determinations are slow by design. The agency can take many months, and in complex cases more than a year, to move from a formal coverage request through evidence review to a national or local determination. Diagnostics have historically fared worse in this process than therapeutics, because the statutory framework for Medicare coverage of items and services does not automatically accommodate novel test categories. Congress has repeatedly had to legislate pathways into existence for new diagnostic classes rather than rely on CMS to create them administratively.

The precedent list is instructive. Blood-based screening and genomic panel tests that cleared FDA review have nonetheless spent years in coverage limbo. The pattern repeats: a favorable regulatory decision generates headlines and a stock move, then the company discloses that reimbursement discussions are ongoing, then revenue guidance slips. Investors who treat FDA backing as the finish line have repeatedly been wrong-footed by the payer process that follows.

Why Investors Are Betting Big on Grail

The bull case rests on market size. Analysts covering the diagnostics space have framed MCED screening as a potentially tens-of-billions-of-dollars annual market if it achieves guideline inclusion and broad reimbursement, a figure that assumes adoption at scale across the Medicare population and eventually younger commercially insured adults. Even a modest penetration rate against that base produces revenue that dwarfs the current diagnostics market for single-cancer screening blood tests.

Grail has also attracted attention because of its ownership history. The company was spun out of Illumina, the dominant player in DNA sequencing, and later reacquired by it before being spun out again following regulatory pressure in the United States and Europe over vertical integration in the sequencing market. That lineage matters analytically: it signals that the sequencing cost curve, which has fallen dramatically over the past decade, is central to the unit economics of any high-volume blood-based screening product. A test that costs too much to run cannot be sold profitably at population scale regardless of what payers agree to pay.

The investor enthusiasm, then, is a bet on three stacked propositions: that the science holds, that regulators accept it, and that payers eventually pay for it. The FDA panel vote strengthens the second proposition. It does nothing for the third.

The Business Risk: Revenue Depends on Insurer Buy-In

Here is the arithmetic that matters. A screening test sold to consumers at out-of-pocket prices generates limited volume, because few patients pay hundreds of dollars for a test their doctor did not order and their insurer will not cover. Volume comes from physician adoption, and physician adoption in screening follows guidelines and reimbursement. The United States Preventive Services Task Force grades screening services, and payers — including Medicare — generally align coverage with those grades. An MCED test without a USPSTF grade faces a structural coverage headwind that no FDA decision can clear.

That creates a specific and identifiable business risk: Grail can hold an FDA-backed product and still post revenue far below what the market has priced in, for the simple reason that the reimbursement code, the coverage determination, and the guideline recommendation are all separate gates. Passing one gate does not open the next.

The company's cost structure compounds the risk. Building a clinical evidence base large enough to satisfy CMS and USPSTF reviewers requires multi-year, multi-thousand-patient studies, and those studies are expensive. If coverage is delayed, the company funds evidence generation from a revenue base that hasn't scaled. That is the classic diagnostics trap, and it has claimed more than one well-regarded laboratory company.

What Happens Next: Timeline and Key Decision Points

The immediate next step is the FDA's final decision on the Galleri application. A favorable panel vote typically precedes clearance, though the agency is not obligated to follow panel recommendations and has departed from them in both directions.

The more consequential track runs through CMS. A formal coverage pathway requires either a national coverage determination, which is a lengthy and public evidence review, or local coverage determinations issued by Medicare Administrative Contractors, which can produce a patchwork of regional coverage. Companies in Grail's position typically pursue both while simultaneously seeking a reimbursement code from the appropriate coding authorities so that, if coverage arrives, claims can actually be processed.

Watch for three signals over the next several quarters: whether Grail discloses a formal CMS coverage submission, whether the USPSTF opens an evidence review for MCED screening, and whether the company's revenue guidance begins to reflect reimbursement timing rather than test volume. The first two are process milestones. The third is the tell.

Implications for Patients, Payers, and the Broader Healthcare Market

For patients, an FDA-backed MCED test changes the conversation with their physicians but not the bill. A test that is available and a test that is covered are different products from the patient's perspective, and the gap between them is where most of the near-term disappointment will live.

For payers, MCED screening presents a genuine actuarial puzzle. A test that detects cancer earlier could reduce spending on late-stage treatment, which is where the largest oncology costs concentrate. It could also generate a cascade of follow-up imaging, biopsies, and procedures in patients whose test flags a signal that turns out not to be cancer — the false-positive problem that has shadowed every screening modality ever adopted. Payers will demand evidence on both sides of that ledger before writing a coverage policy.

For the broader healthcare market, the Grail case is a template. Diagnostics companies increasingly win regulatory validation faster than they win reimbursement, and the gap between those two events is where investment returns are made or destroyed. The FDA panel vote is real progress. The harder fight — the one that determines whether Galleri becomes a standard of care or a cautionary tale — is only now beginning.

Source: WSJ.com: Markets